Study of Histopathological Spectrum and Immunohistochemical Correlation in Breast Carcinoma

Background of the Study Breast carcinoma remains the most common malignancy among women worldwide and is a leading cause of cancerrelated morbidity and mortality. The disease exhibits remarkable heterogeneity in its morphological, molecular, and clinical behavior, which significantly influences prognosis and therapeutic response. Histopathological evaluation has long been considered the gold standard for diagnosis, classification, and grading of breast carcinoma. It provides essential information regarding tumor architecture, cellular morphology, and invasiveness, forming the foundation for clinical decision-making (Schnitt SJ, 2016; Rakha EA & Ellis IO, 2017). However, with advancements in molecular oncology, it has become evident that histopathology alone cannot fully capture the biological diversity of breast cancer. Immunohistochemistry (IHC) has emerged as a crucial adjunct tool that enables the identification of specific protein markers within tumor cells. Key biomarkers such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2/neu), and Ki-67 proliferation index are now routinely used for molecular classification and prognostication (Cimino-Mathews A, 2021; Rakha EA & Ellis IO, 2022). These markers help categorize breast carcinoma into intrinsic subtypes such as Luminal A, Luminal B, HER2- enriched, and triple-negative breast cancer, each with distinct therapeutic implications (Perou CM & Sørlie T, 2015; Goldhirsch A et al., 2017). Recent studies have further emphasized the role of emerging biomarkers and advanced immunohistochemical techniques in improving diagnostic accuracy and understanding tumor biology (Mandair D et al., 2023; Varga Z & Maccio U, 2024). Therefore, correlating histopathological findings with immunohistochemical expression is essential for a comprehensive evaluation of breast carcinoma. Aim and Objectives To study the histopathological spectrum of breast carcinoma and correlate it with immunohistochemical marker expression. Objectives:  To analyze the distribution of various histopathological types of breast carcinoma.  To evaluate tumor grading using standard histological criteria.  To assess the expression of key immunohistochemical markers (ER, PR, HER2/neu, Ki-67).  To establish correlation between histopathological features and immunohistochemical profiles.  To determine the prognostic significance of combined histopathological and IHC findings. Methodology This study was conducted as a prospective and/or retrospective observational study in the Department of Pathology at a tertiary care center. A total number of breast carcinoma cases diagnosed over a specified study period were included. Formalin-fixed, paraffin-embedded tissue sections were subjected to routine hematoxylin and eosin (H&E) staining for histopathological evaluation. Tumors were classified according to the World Health Organization (WHO) classification of breast tumors (WHO, 2019). Histological grading was performed using the Nottingham grading system, which assesses tubule formation, nuclear pleomorphism, and mitotic activity (Rakha EA & Tse GM, 2016). Immunohistochemical analysis was carried out using standardized protocols for ER, PR, HER2/neu, and Ki-67 markers, following ASCO/CAP guidelines (Wolff AC et al., 2018; Allison KH et al., 2020). The expression patterns were interpreted and categorized based on established scoring systems. Statistical analysis was performed to evaluate the correlation between histopathological parameters and immunohistochemical findings. Results The study demonstrated that invasive ductal carcinoma (no special type) was the most common histopathological subtype, followed by invasive lobular carcinoma and other special variants such as mucinous and papillary carcinoma (Geyer FC & Pareja F, 2019). The majority of cases were categorized as intermediate to high grade based on the Nottingham grading system. Immunohistochemical analysis revealed that a significant proportion of tumors were positive for hormone receptors (ER and PR), while a subset showed HER2 overexpression. Ki-67 proliferation index varied widely, indicating differences in tumor aggressiveness. Correlation analysis showed that hormone receptor positivity was more commonly associated with lower-grade tumors, whereas HER2 positivity and high Ki-67 index were associated with higher-grade, more aggressive tumors (Hacking SM et al., 2022; Moustafa M et al., 2023). Triple-negative breast cancers were found to be predominantly high-grade tumors with poor prognostic features (Foulkes WD & Smith IE, 2016). Conclusion The study highlights the diverse histopathological spectrum of breast carcinoma and underscores the critical role of immunohistochemistry in its comprehensive evaluation. The integration of histopathological findings with immunohistochemical markers provides valuable insights into tumor biology, enabling accurate classification, prognostication, and personalized treatment planning. The findings confirm that combined assessment improves diagnostic precision and helps identify clinically significant subtypes, particularly aggressive variants such as triple-negative and HER2-positive tumors. Recommendations  Routine use of immunohistochemical markers in all diagnosed breast carcinoma cases for accurate classification.  Adoption of standardized protocols and guidelines (ASCO/CAP) to ensure consistency in biomarker evaluation.  Incorporation of newer and emerging biomarkers to enhance diagnostic and prognostic accuracy.  Multidisciplinary approach involving pathologists, oncologists, and surgeons for optimal patient management.  Further large-scale studies with long-term follow-up to validate prognostic correlations. Summary Breast carcinoma is a heterogeneous disease requiring a multidimensional diagnostic approach. Histopathology remains the cornerstone of diagnosis, while immunohistochemistry provides essential molecular insights. The correlation between morphological features and biomarker expression enhances understanding of tumor behavior and guides therapeutic decisions. This study reinforces the importance of integrating histopathological and immunohistochemical evaluation in modern breast cancer diagnosis and management.